EPCAM and neoplasm: It was shown that low doses of the α-amanitin-conjugated anti-epithelial cell adhesion molecule (EpCAM) antibody lead to complete tumor regression in mouse models of human colorectal cancer with hemizygous deletion of POLR2A [24].